The observed expression patterns of EP300, SIRT1 and SIRT6 suggested that they are unlikely to be responsible for FOXO3 activation by Lapatinib, even though EP300, SIRT1 and SIRT6 could still modulate FOXO3 acetylation and activity in these NPC cells. The gene discussed is FOXO3; the disease is nasopharyngeal carcinoma.